Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as its lead preclinical development candidate for the treatment of drug-resistant B-cell lymphomas and potentially for the treatment of JAM-C (+) solid tumours.
top of page
Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...
Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...
Geneva, Switzerland, May 26, 2021 – Abologix has been named one of the winners of the Venture Kick stage III start up competition. This...
bottom of page
Kommentare